Viatris Inc (VTRS)

Currency in USD
9.08
+0.15(+1.68%)
Closed·
After Hours
9.08+0.01(+0.11%)
·
VTRS Scorecard
Full Analysis
Management has been aggressively buying back shares
High dividend Yield
Fair Value
Day's Range
8.899.10
52 wk Range
6.8513.55
Key Statistics
Prev. Close
8.93
Open
8.99
Day's Range
8.89-9.1
52 wk Range
6.85-13.55
Volume
8.07M
Average Vol. (3m)
13.42M
1-Year Change
-20.21%
Book Value / Share
13.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VTRS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.39
Upside
+25.41%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Viatris Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Viatris Inc Company Profile

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Employees
32000

Viatris Inc SWOT Analysis


Analyst Perspectives
Gain insights from varied analyst ratings, with price targets ranging from $10 to $12, reflecting the complex landscape Viatris operates within
Growth Trajectory
Discover Viatris's potential for revenue expansion, with forecasts surpassing consensus estimates and new product launches driving future performance
Financial Health
Delve into Viatris's robust EBITDA of $4.22 billion, attractive dividend yield, and management's focus on shareholder value through aggressive buybacks
Generic Drug Dynamics
Explore Viatris's strategic positioning in the complex generics market, navigating sector headwinds while capitalizing on innovation-driven growth opportunities
Read full SWOT analysis

Viatris Inc Earnings Call Summary for Q1/2025

  • Q1 2025 EPS of $0.50 and revenue of $3.25B missed forecasts; stock rose 8.84% pre-market despite miss
  • Revenue down 2% YoY, but company reaffirmed full-year outlook with 52% of revenues expected in H2 2025
  • $2.9B non-cash goodwill impairment charge reported; free cash flow at $493M ($535M excluding divestiture costs)
  • Company targets $450-$550M in new product revenue; progressing on innovative pipeline with products nearing submission
  • Share repurchase plan completed $300M, targeting $500-$650M; strong focus on returning capital to shareholders
Last Updated: 05/08/2025, 09:48 AM
Read Full Transcript

Compare VTRS to Peers and Sector

Metrics to compare
VTRS
Peers
Sector
Relationship
P/E Ratio
−2.8x3.3x−0.5x
PEG Ratio
0.00−0.010.00
Price / Book
0.7x3.1x2.6x
Price / LTM Sales
0.7x1.9x3.2x
Upside (Analyst Target)
34.4%411.9%45.4%
Fair Value Upside
Unlock16.5%6.7%Unlock

Analyst Ratings

3 Buy
6 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 11.39
(+25.41% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -3.18%
Dividend Yield
5.29%
Annualized Payout
0.48
Paid unevenly
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
0.50 / 0.51
Revenue / Forecast
3.25B / 3.33B
EPS Revisions
Last 90 days

VTRS Income Statement

People Also Watch

30.41
CNC
+1.37%
109.43
LEN
+1.58%
165.71
FI
+0.78%
292.49
UNH
+0.27%
113.32
TFX
-0.13%

FAQ

What Is the Viatris (VTRS) Stock Price Today?

The Viatris stock price today is 9.08

What Stock Exchange Does Viatris Trade On?

Viatris is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Viatris?

The stock symbol for Viatris is "VTRS."

Does Viatris Pay Dividends? What’s The Current Dividend Yield?

The Viatris dividend yield is 5.29%.

What Is the Viatris Market Cap?

As of today, Viatris market cap is 10.66B.

What Is Viatris's Earnings Per Share (TTM)?

The Viatris EPS (TTM) is -3.18.

When Is the Next Viatris Earnings Date?

Viatris will release its next earnings report on Aug 07, 2025.

From a Technical Analysis Perspective, Is VTRS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Viatris Stock Split?

Viatris has split 11 times.

How Many Employees Does Viatris Have?

Viatris has 32000 employees.

What is the current trading status of Viatris (VTRS)?

As of Jul 17, 2025, Viatris (VTRS) is trading at a price of 9.08, with a previous close of 8.93. The stock has fluctuated within a day range of 8.89 to 9.10, while its 52-week range spans from 6.85 to 13.55.

What Is Viatris (VTRS) Price Target According to Analysts?

The average 12-month price target for Viatris is USD11.3875, with a high estimate of USD14 and a low estimate of USD8. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Neutral. The stock has an +25.41% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.